Management describes as much as $50 million of financing for Adrenyx, but only $5 million has been funded so far, through secured convertible notes. The proposed distribution also carries a potential tax bill for shareholders even if they receive shares rather than cash. Those two details deserve more attention than the creation of a second biotechnology ticker.
Two drug programs, two publicly traded companies
Adrenyx will develop CRHX-101, previously called SPR-202, an investigational monoclonal antibody intended to address excessive adrenal androgen production in classic congenital adrenal hyperplasia (CAH). It is still at the late preclinical stage: the new company must finish work needed for an investigational new drug application before starting clinical trials. Its prospects depend on clinical development that has yet to establish safety and efficacy in patients.
Spruce will retain tralesinidase alfa enzyme replacement therapy (TA-ERT), its lead candidate for mucopolysaccharidosis type IIIB, also known as Sanfilippo syndrome type B. Spruce is targeting a biologics license application filing in December 2026, seeking accelerated FDA approval, and has begun an expanded-access program. That places Spruce closer to a potential regulatory decision than Adrenyx, although approval and commercial success remain uncertain for both businesses.
| Spruce Biosciences | Adrenyx Biosciences | |
|---|---|---|
| Principal program | TA-ERT for MPS IIIB | CRHX-101 for classic CAH |
| Next development milestone | Planned December 2026 BLA submission | IND-enabling work, then an FDA filing and clinical trials |
| Leadership | CEO Javier Szwarcberg | CEO Samir Gharib |
| Trading status | Nasdaq: SPRB | Nasdaq listing sought; ticker not announced |
Gharib is currently Spruce’s president and chief financial officer and is expected to continue in those roles while leading Adrenyx. Spruce will also provide Adrenyx with transitional services for up to 12 months after the distribution, at cost and without a markup. Separate listings will therefore begin with some shared leadership and operating support.
What the $50 million financing announcement actually means
Adrenyx issued $5 million of secured convertible notes on November 6. Its agreement permits up to another $5 million of notes, subject to conditions including investor consent, and Spruce expects an Adrenyx equity private placement in connection with the distribution. The investor could provide up to $50 million in total, including the notes; this is not $50 million of cash already sitting on Adrenyx’s balance sheet, nor $50 million on top of the note financing.
The November 9 Form 10-Q adds terms absent from the headline announcement. The initial notes carry 6% annual cash interest, mature 12 months after issuance and automatically convert in certain equity financings, including a qualifying $37.5 million financing, at 90% of the price paid by new investors. They are secured by substantially all Adrenyx assets, but Spruce does not guarantee them or pledge its own assets.
Financing gives the preclinical program resources to pursue development, while conversion and new equity issuance can dilute the ownership percentage ultimately represented by shares distributed to existing Spruce holders. The price and full size of that equity financing have not been disclosed, so the $50 million figure does not establish Adrenyx’s equity valuation. Spruce shareholders also cannot yet calculate their prospective Adrenyx ownership from a distribution ratio: none has been announced.
A taxable distribution adds another variable
Unlike the tax-free treatment sought in many corporate spinoffs, Spruce expects its Adrenyx share distribution to be taxable for U.S. federal income tax purposes. Its separation agreement expressly contemplates a taxable transaction, and the 10-Q warns that stockholders may be treated as receiving a distribution measured by the fair market value of their Adrenyx shares. Investors could therefore incur a tax liability without receiving cash from the transaction.
Spruce itself may recognize taxable gain, with potential limits on the use of its net operating losses to offset it. The ultimate amounts depend on the companies’ values and tax circumstances when the distribution occurs, so a present per-share tax estimate would be premature. StockSpinoffs has covered another unusual taxable biotech separation, AnaptysBio’s distribution of First Tracks, but that precedent does not determine the tax result for Spruce investors.
Spruce’s balance sheet still matters
Spruce reported $87.7 million of cash at September 30 and used $44.6 million in operating cash during the first nine months of 2026. Although its earnings release says that cash should support planned operations and debt obligations into the second half of 2027, the 10-Q also says current cash would be insufficient to fund at least 12 months of operations and obligations without other financing or strategic proceeds, raising substantial doubt about its ability to continue as a going concern. The company amended its Avenue borrowing agreement on November 6 to change the timing and availability of additional loans.
The Adrenyx note proceeds cannot be used to fund Spruce’s operations. Separating the programs may help each seek capital on its own terms, but it does not eliminate either company’s need to finance drug development. The independent businesses will ultimately be valued on their different regulatory prospects, cash requirements and shareholder dilution, rather than on the number of shares created by the transaction.
Spruce’s board still must approve the actual distribution, an Adrenyx registration statement must become effective, and Nasdaq must approve the new listing. There is no record date, distribution ratio or Adrenyx ticker yet, and the planned first-half-2027 completion could change. The next disclosures worth watching are the private-placement price and resulting capitalization, the shareholder distribution terms, and the tax information provided before the shares are delivered.